The global cardiovascular therapeutic drug market was worth $140.7 billion in 2009, and is expected to grow by a compound annual growth rate (CAGR) of 2.7% to $144.5 billion in 2010. This market will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to reach $139.8 billion in 2015, a CAGR of -0.7%.
The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies. The market is expected to grow to $65.3 billion in 2010 and experience a reduction through 2015 to $53.7 billion, a compound annual growth rate (CAGR) of -3.9%.
Treatment for hyperlipidemia recorded sales of more than $33 billion in 2009. Large therapeutic drugs including Lipitor and Crestor comprise a high concentration of this segment. Driven by patent expirations for Lipitor, and other drugs within this segment, the segment will shrink to about $26 billion by 2015, a CAGR of -4.3%.
STUDY GOALS AND OBJECTIVES
This study provides a comprehensive analysis of cardiovascular therapies on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the market for therapeutic drug products in the cardiovascular segment. Individual products are forecast on a global basis, as are overall segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast.
REASONS FOR DOING THE STUDY
For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute to capture profit from opportunity.
The cardiovascular therapeutic market is the largest of any drug sector. In addition, companies that hold patent rights to the largest drug classes have elected to exit the sector, opening the market up to the next tier of participants.
Market growth has been spurred by the introduction of differentiated therapies due to novel mechanism of action, such as P2Y12 inhibitors and Factor Xa inhibitors. In contrast to technical innovation, patent expiry is producing a severe headwind as evidenced by Lipitor and Plavix which are expected to drop $19 billion in one-year sales in 2015 from 2010.
This study investigates one of the most important market drivers: the introduction of combination therapies, which are expected to continue to contribute substantially to market growth through the forecast period. Combination therapies for hypertension are anticipated, as evidenced by Valturna (Novartis, Diovan and Tekturna) and Exforge (Novartis, Diovan and amlodipine).
This report analyzes emerging markets, by disease segment. Continued growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil and Russia.
This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies in order to allocate resources and make effective decisions.
SCOPE OF REPORT
Current and projected product forecasts during the forecast period (2010 to 2015) are discussed. As well, new products approved in 2009 and 2010 by the FDA, and those products expected to be approved within the forecast period are projected. 2010 is an estimated figure, except where actual results have been reported, due to the release timing of the report. For large markets segments such as hypertension, hyperlipidemia, and thrombosis, specific mechanisms of action are discussed in detail. For example, the trend of increased use of statins as a first-line therapy as compared to beta blockers and heparin therapies is analyzed. For each core segment within the overall market, leading products are analyzed for their differentiation by mechanism of action. The attempt to pursue and seek approval for PDE5 inhibitors is discussed in detail.
The report includes analysis of leading and emerging competitors in the current worldwide cardiovascular market. Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.
Market figures are based on revenues at the manufacturers’ level and are projected at 2010-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.
Included in this report are forecasts by product, product category, and by company from 2009 through 2015. The study is arranged to offer an overview of the cardiovascular market accompanied by product, company, geography, and mechanism of action with forecasts broken down and covered by geographic region or country. Virtually the entire globe is covered to include prevalence data, for each disease sub segment.
Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician’s prescription.
Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the cardiovascular market, its products, its industry participants and its future.
The importance of identifying overall market trends, product opportunities, emerging geographies, M&A opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:
Established companies in the industry will benefit from the contents, including corporate strategy, sales and marketing, business development, and R&D.
Emerging biotechnology players in the segment must understand specific opportunities for out-licensing, originating from the elements of differentiation of their therapeutic drug as compared to leading, competitive, and emerging therapies. As well, market forecasts can support investment, provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.
Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunity and risks that are being encountered in the industry, in a product and company specific analysis.
Equity analysts are provided detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.
METHODOLOGY AND INFORMATION SOURCES
In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading medical practitioners in the field.
Information to prepare this report was obtained from participating and emerging companies in the cardiovascular area; American Heart Association, the National Heart, Lung and Blood Institute and the National Heart, Lung, and Blood Institute; articles published in medical journals such as American Heart Journal, Circulation, Journal of Cardiovascular Pharmacology, Lancet, and others; the World Health Organization and other government agencies; literature searches; annual reports; 10Ks; and others. Population estimates are based on those reported by the International data base of the U.S. Census Bureau.
Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Published - Apr-2001|
Analyst - Lynn Gray|
Code - PHM024A
Worldwide sales of cardiovascular drugs approached $47 billion in 1999, and the leading 15 products in the class generated sales of approximately $18 billion. Cardiovascular drugs discussed in this report comprise adrenergic inhibitors, adrenergic stimulators, angiotensin converting enzyme (ACE) inhibitors, angiotensin II inhibitors, antithrombics, beta blockers, calcium channel blockers, diuretics, steroids and steroidal glycosides, vasodilators, vasopressors, and others.
Market applications reviewed in this report include acute coronary syndrome, angina, arrhythmia, atherosclerosis, congestive heart failure, coronary artery disease, deep vein thrombosis, edema, hypercholesterolemia, hypertension, hypotension, myocardial infarction and stroke.
Angiotension II inhibitors, which are indicated for the treatment of heart failure and hypertension, are projected to see an average annual growth of nearly 20% and the antithrombic category will see growth approaching 16% throughout the forecast period (2000-2005).
Need a custom data table, graph or complete report? Tell us more.
Download Report Overview - Cardiovascular Therapeutic Drugs: Technologies and Global Markets
Complete the form below and we'll send you a private, secure link to download the Report Overview as a PDF.
* All fields are required
Join our mailing list for the latest report releases and upcoming event notifications.
Thank you for your interest in BCC Research. You will be added to our mailing list.
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.